Navigation Links
FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010
Date:12/23/2009

Agency Experts to Provide Guidance on Applying for Orphan Drug Designation

SILVER SPRING, Md., Dec. 23 /PRNewswire-USNewswire/ -- As part of its continuing effort to make the agency more transparent and accessible, the FDA has scheduled a series of workshops about orphan drug designation for academics, biotechnology companies, and those unfamiliar with the process. The FDA can grant a special status, known as orphan designation, for drug products intended to treat rare diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Orphan drugs are either drug or biologic products used to treat conditions affecting fewer than 200,000 people in the United States. Orphan drugs may be already-approved or experimental drugs.

The workshops will be held Feb. 25-26, 2010, in Claremont, Calif., and Aug. 3-4, 2010, in Minneapolis. At the workshops, participants will propose a specific drug for a specific rare disease and work on an orphan designation application to submit to the FDA at the conclusion of the workshop. To help participants develop strong applications, FDA staff will provide one-on-one regulatory help.

To obtain orphan drug designation, drugs must be for the treatment, prevention or diagnosis of a rare disease or condition. Designation also requires there be a medical rationale for expecting the proposed drug to be effective in the treatment, prevention, or diagnosis of that disease or condition.

Orphan designation qualifies the applicant to receive certain benefits, such as tax credits and marketing incentives, from the federal government in exchange for developing the drug. After designation, the drug must then be submitted for review through the FDA marketing approval process, which evaluates the drug for safety and efficacy.

During the past 25 years, the FDA has granted orphan drug designation to about 2,100 drugs, of which 344 have become approved products.

For more information:

Do a Designation: FDA Orphan Drug Workshops

http://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM189586.pdf

Designating an Orphan Product: Drugs and Biologics

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm


    Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
    Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
3. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
4. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
5. Voices to Unite in Los Angeles for 6,000 Children Orphaned Daily
6. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor ... story and encourage those at risk to get tested and begin the road to a ... ... ... Pharmacy, Inc.) ...
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
(Date:5/3/2016)... 2016 Intec Pharma Ltd. (NASDAQ: ... company, today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in ... outstanding track record, having supported the advancement of several ... in the United States and ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Park Cities Pet Sitter has openings ... to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 ... Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas of the Metroplex. ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... as one of Canada’s top Information and Communication Technology (ICT) companies in the ... and Multinational ICT companies operating in Canada, as ranked by revenue. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... the latest release of DocAve 6 Service Pack (SP) 7, the ... to SharePoint 2016 and take advantage of the platform’s latest features – whether ...
(Date:5/3/2016)... ... 2016 , ... Hydra Skin Sciences, a top-rated skincare company based ... new anti-aging skin care product that integrates Snow Algae Powder and six ... seventy-five thousand units worldwide within the first two months of release. , “We set ...
(Date:5/3/2016)... ... May 03, 2016 , ... On ... the line’s largest cruise ship ever. To help guests explore this new ... the Carnival Vista ’s most exciting features and accommodations. , Explore ...
Breaking Medicine News(10 mins):